Sell 10/4/2023Downgrade
Adaptive Biotechnologies Corporation (ADPT) was downgraded to E+ from D- on 10/4/2023 due to a decline in the total return index and volatility index.

Sell 8/18/2023Upgraded
Adaptive Biotechnologies Corporation (ADPT) was upgraded to D- from E+ on 8/18/2023 due to an increase in the volatility index and valuation index.

Sell 8/3/2023Downgrade
Adaptive Biotechnologies Corporation (ADPT) was downgraded to E+ from D- on 8/3/2023 due to a decline in the volatility index and valuation index.

Sell 7/21/2023Upgraded
Adaptive Biotechnologies Corporation (ADPT) was upgraded to D- from E+ on 7/21/2023 due to an increase in the total return index and volatility index.

Sell 6/14/2023Downgrade
Adaptive Biotechnologies Corporation (ADPT) was downgraded to E+ from D- on 6/14/2023 due to a decline in the valuation index.

Sell 5/30/2023Upgraded
Adaptive Biotechnologies Corporation (ADPT) was upgraded to D- from E+ on 5/30/2023 due to an increase in the valuation index.

Sell 5/11/2023Downgrade
Adaptive Biotechnologies Corporation (ADPT) was downgraded to E+ from D- on 5/11/2023 due to a substantial decline in the growth index, total return index and volatility index. Operating cash flow declined 97.05% from -$30.02M to -$59.15M, EBIT declined 52.17% from -$37.59M to -$57.19M, and earnings per share declined from -$0.2805 to -$0.4021.

Sell 3/14/2023Downgrade
Adaptive Biotechnologies Corporation (ADPT) was downgraded to D- from D on 3/14/2023 due to a decline in the total return index and volatility index.

Sell 2/16/2023Upgraded
Adaptive Biotechnologies Corporation (ADPT) was upgraded to D from D- on 2/16/2023 due to a large increase in the growth index, total return index and solvency index. Operating cash flow increased 29.21% from -$42.41M to -$30.02M, EBIT increased 17.27% from -$45.43M to -$37.59M, and total revenue increased 15.4% from $47.83M to $55.2M.

Sell 2/8/2023Downgrade
Adaptive Biotechnologies Corporation (ADPT) was downgraded to D- from D on 2/8/2023 due to a decline in the solvency index and valuation index.

Sell 5/27/2022Upgraded
Adaptive Biotechnologies Corporation (ADPT) was upgraded to D from D- on 5/27/2022 due to an increase in the growth index and valuation index. Total revenue increased 1.82% from $37.93M to $38.62M.

Sell 5/5/2022Upgraded
Adaptive Biotechnologies Corporation (ADPT) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index and growth index.

Sell 4/20/2022Downgrade
Adaptive Biotechnologies Corporation (ADPT) was downgraded to E+ from D- on 4/20/2022 due to a decline in the total return index and solvency index.

Sell 3/28/2022Downgrade
Adaptive Biotechnologies Corporation (ADPT) was downgraded to D- from D on 3/28/2022 due to a large decline in the total return index, volatility index and solvency index. The quick ratio declined from 3.55 to 3.26.

Sell 11/23/2021Upgraded
Adaptive Biotechnologies Corporation (ADPT) was upgraded to D from D- on 11/23/2021 due to an increase in the total return index and valuation index.

Sell 11/8/2021Downgrade
Adaptive Biotechnologies Corporation (ADPT) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index and solvency index. The quick ratio declined from 5.27 to 3.55, operating cash flow declined 16.74% from -$37.21M to -$43.44M, and EBIT declined 13.18% from -$49.77M to -$56.33M.

Sell 6/2/2020Upgraded
Adaptive Biotechnologies Corporation (ADPT) was upgraded to D from D- on 6/2/2020 due to a noticeable increase in the growth index, volatility index and total return index.

Sell 5/15/2020Downgrade
Adaptive Biotechnologies Corporation (ADPT) was downgraded to D- from D on 5/15/2020 due to a major decline in the efficiency index, volatility index and growth index. Net income declined 52.36% from -$20.61M to -$31.4M, earnings per share declined from -$0.1657 to -$0.2491, and EBIT declined 43.13% from -$24.19M to -$34.62M.

Sell 9/20/2019None
Adaptive Biotechnologies Corporation (ADPT) was downgraded to D from U on 09/20/2019.